Partnership Opportunities

AOP Orphan, Activartis’ parent company, specialises in the development and marketing of new therapies for rare and complex diseases. AOP and Activartis’ management is committed to developing and commercialisation its novel cancer immune therapy technology in selected markets. We also welcome the opportunity to work in collaboration with partners and to out-license Activartis’ cancer immune therapy technology to major pharmaceutical and biotechnology companies.

In terms of licensing Activartis is currently seeking an international partner with the capabilities of supporting a phase III trial and commercialisation in larger markets .

More specifically, we are looking for a licensing partner for:

• Co-development of Activartis’ cancer vaccine in phase III for the treatment of brain cancer
• Global expertise in marketing and distribution of  biologics especially in oncology  to commercialise Activartis’  brain cancer vaccine
• Co-development of Activartis’ cancer immune therapy technology in other neoplastic diseases
• We are also open to approaches from potential partners interested in licensing specific geographical regions or indications.

To discuss collaborating or licensing opportunities with Activartis, or to arrange a meeting with Activartis’ Business Development team, please contact Douglas Lloyd Fell:

Douglas Lloyd Fell
douglas.lloyd-fell(at)activartis.com
+ 44 7770 445 268

Where to meet us

Bio Europe Conference
October 31 – November 2, 2011
Düsseldorf, Germany
www.ebdgroup.com/bioeurope